CN Mobile Logo


Testicular Cancer

Post-Surgery Surveillance Found Safe in Seminoma

Surveillance of patients with stage I seminoma following orchiectomy can spare a majority of patients from adjuvant chemotherapy with a low risk of relapse, according to results presented at the 2013 ASCO meeting.

Testicular Cancer

Patients who have undergone chemotherapy for nonseminoma testicular cancer are at an increased risk for cardiovascular disease, especially in the first year after treatment.

Patients with a history of testicular cancer had a fivefold higher risk of developing aggressive prostate cancer when compared with those with no history of testicular cancer.

Active surveillance is effective and yields good outcomes in patients with clinical stage I testicular cancer who underwent orchiectomy.

When relapse occurs in patients with germ cell tumors, two salvage treatment paradigms exist: standard-dose chemotherapy, or high-dose chemotherapy with autologous stem cell rescue.

Results of a combined analysis of SWENOTECA studies showed that surveillance remains a good option for patients with stage I seminoma testicular cancer.

The addition of gemcitabine to a cisplatin- and ifosfamide-containing drug regimen resulted in a complete response rate of greater than 50% in patients with relapsed metastatic germ cell tumors, results of a phase II study indicated.

Cisplatin-based chemotherapy has transformed the prognosis of testicular germ cell cancer (GCT). It has converted the chief mortal malignancy in younger men into a model for the curability of cancer.


Subscribe to Testicular Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.